What is Leerink Partnrs’ Forecast for ALDX FY2024 Earnings?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Stock analysts at Leerink Partnrs dropped their FY2024 EPS estimates for Aldeyra Therapeutics in a note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst M. Goodman now forecasts that the biotechnology company will post earnings per share of ($0.95) for the year, down from their previous estimate of $0.70. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.89) per share. Leerink Partnrs also issued estimates for Aldeyra Therapeutics’ Q4 2024 earnings at ($0.28) EPS, FY2025 earnings at $2.00 EPS and FY2026 earnings at ($0.05) EPS.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) EPS for the quarter, meeting analysts’ consensus estimates of ($0.25).

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a research report on Friday, August 9th.

Aldeyra Therapeutics Price Performance

Aldeyra Therapeutics stock opened at $4.70 on Monday. Aldeyra Therapeutics has a 12 month low of $2.43 and a 12 month high of $6.55. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. The business has a 50 day simple moving average of $5.45 and a 200-day simple moving average of $4.60.

Institutional Investors Weigh In On Aldeyra Therapeutics

Several large investors have recently bought and sold shares of ALDX. BNP Paribas Financial Markets lifted its position in shares of Aldeyra Therapeutics by 23.4% in the first quarter. BNP Paribas Financial Markets now owns 25,278 shares of the biotechnology company’s stock valued at $83,000 after acquiring an additional 4,797 shares in the last quarter. Acadian Asset Management LLC raised its stake in Aldeyra Therapeutics by 106.3% in the 1st quarter. Acadian Asset Management LLC now owns 452,449 shares of the biotechnology company’s stock valued at $1,478,000 after purchasing an additional 233,169 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Aldeyra Therapeutics by 7.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 48,273 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 3,446 shares in the last quarter. Kennedy Capital Management LLC boosted its stake in Aldeyra Therapeutics by 3.3% during the 1st quarter. Kennedy Capital Management LLC now owns 1,318,155 shares of the biotechnology company’s stock worth $4,310,000 after purchasing an additional 42,009 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Aldeyra Therapeutics during the first quarter worth $585,000. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.